Quanterix today announced an initial public offering of nearly 2.4 million shares of common stock at $25.25 apiece for which it expects to gross $60 million.
Billerica, Mass.-based Quanterix is developing a digital approach to immunoassays to allow single molecules to be counted. Its technology is used in the therapeutic areas of oncology, neurology, cardiology, inflammatory and infectious disease.
Quanterix set the floatation at $25.25 per share on 2,376,238 shares of its common stock, giving underwriters a 30-day option to purchase up to an additional 356,435 shares of common stock on the same terms and conditions. Before deductions, the company expects gross proceeds to be $60 million.
Shares are slated to trade on the NASDAQ exchange under the symbol QTRX until Aug. 13, subject to customary closing conditions, according to the company.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!